NCT00918268View on ClinicalTrials.gov

Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Influenza Disease
Interventions
BIOLOGICAL

Influenza vaccine

One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010

Trial Locations (3)

30030

Pianiga Distretto n. 2 - Area Sud - Azienda ULSS 13 Mirano-Via Nazionale 48, Pianiga

66034

Ufficio Igiene e Sanità Pubblica di Lanciano, ASL Lanciano - Vasto, sede legale Via S. Spaventa, 37 ----- Satellite sites: (a) Distretto Sanitario di Base, Via Don Minzoni, Lanciano (CH) and (b) Distretto Sanitario di Base, Via Polidoro, Fossacesia (CH)), Lanciano

66100

Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. D'Annunzio, Via dei Vestini, Chieti

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY

NCT00918268 - Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects | Biotech Hunter | Biotech Hunter